22.04.2018 Fresenius SE & Co. KGaA  DE0005785604

DGAP-Adhoc: Fresenius SE & Co. KGaA: Fresenius terminates merger agreement with Akorn


 
DGAP-Ad-hoc: Fresenius SE & Co. KGaA / Key word(s): Mergers & Acquisitions Fresenius SE & Co. KGaA: Fresenius terminates merger agreement with Akorn 22-Apr-2018 / 19:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Fresenius terminates merger agreement with Akorn Fresenius has decided today to terminate the company's merger agreement with Akorn, due to Akorn's failure to fulfill several closing conditions. Fresenius' decision is based on, among other factors, material breaches of FDA1 data integrity requirements relating to Akorn's operations found during Fresenius' independent investigation. Fresenius offered to delay its decision in order to allow Akorn additional opportunity to complete its own investigation and present any information it wished Fresenius to consider, but Akorn has declined that offer. 1 FDA: Food and Drug Administration Fresenius SE & Co. KGaA, represented by Fresenius Management SE, The Management Board Bad Homburg v.d.H., April 22, 2018 ---------------------------------------- Contact: Markus Georgi Senior Vice President Investor Relations T: +49 (0) 6172 608-2485 [email protected] ---------------------------------------- End of note --------------------------------------------------------------------------- 22-Apr-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: Fresenius SE & Co. KGaA Else-Kröner-Straße 1 61352 Bad Homburg v.d.H. Germany Phone: +49 (0)6172 608-2485 Fax: +49 (0)6172 608-2488 E-mail: [email protected] Internet: www.fresenius.com ISIN: DE0005785604, DE000A2DANS3 WKN: 578560 , A2DANS Indices: DAX Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Hamburg, Hanover, Stuttgart, Tradegate Exchange; Luxemburg End of Announcement DGAP News Service --------------------------------------------------------------------------- 677315 22-Apr-2018 CET/CEST


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 29.083,00 33.530,00 35.409,00 37.250,00 36.277,00 37.520,00 39.695,00
EBITDA1,2 5.500,00 6.267,00 6.032,00 7.083,00 7.132,00 6.854,00 0,00
EBITDA-Marge3 18,91 18,69 17,04 19,01 19,66 18,27 0,00
EBIT1,4 4.327,00 4.589,00 5.251,00 4.631,00 4.385,00 4.252,00 4.990,00
EBIT-Marge5 14,88 13,69 14,83 12,43 12,09 11,33 12,57
Jahresüberschuss1 2.676,00 1.816,00 1.871,00 1.915,00 2.823,00 1.867,00 2.035,00
Netto-Marge6 9,20 5,42 5,28 5,14 7,78 4,98 5,13
Cashflow1,7 3.574,00 3.937,00 3.742,00 4.263,00 6.549,00 5.078,00 5,58
Ergebnis je Aktie8 2,83 3,25 3,37 3,44 3,06 3,26 2,45
Dividende8 0,62 0,75 0,80 0,84 0,88 0,92 0,70
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2021 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: PricewaterhouseCoopers

INVESTOR-INFORMATIONEN
©boersengefluester.de
Fresenius
WKN Kurs in € Einschätzung Börsenwert in Mio. €
578560 27,110 Kaufen 15.269,36
KGV 2024e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
12,32 17,02 0,72 9,28
KBV KCV KUV EV/EBITDA
0,83 3,01 0,41 5,79
Dividende '22 in € Dividende '23e in € Div.-Rendite '22e
in %
Hauptversammlung
0,70 0,70 2,58 17.05.2023
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
09.05.2023 02.08.2023 01.11.2022 24.03.2022
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
2,31% 1,99% 3,28% -26,71%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Fresenius SE & Co. KGaA  ISIN: DE0005785604 können Sie bei EQS abrufen


Medtech , 578560 , FRE , XETR:FRE